Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CD7-H82E4 | Human | Biotinylated Human CD7 Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
CD7-HF257 | Human | FITC-Labeled Human CD7 Protein, Llama IgG2b Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
CD7-HF2H6 | Human | FITC-Labeled Human CD7 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
CD7-H52H7 | Human | Human CD7 Protein, His Tag | ![]() |
![]() ![]() |
|
CD7-H5258 | Human | Human CD7 Protein, Llama IgG2b Fc Tag, low endotoxin | ![]() |
![]() ![]() |
![]() ![]() |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Anti-CD3 ricin chain A conjugate/anti-CD7 ricin chain A conjugate | HENO-3 | Phase 3 Clinical | Xenikos | Graft vs Host Disease | Details |
Anti-CD7 universal CAR-T cell therapy (Chongqing Xinqiao Hospital) | Phase 1 Clinical | Chongqing Xinqiao Hospital | Lymphoma, T-Cell; Leukemia, T-Cell | Details | |
Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy | GC-197 | Phase 2 Clinical | Genxi Biotechnology (Shanghai) Co Ltd | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
RD13-01 | RD13-01 | Clinical | Zhejiang University | Hematologic Neoplasms | Details |
Anti-Cd7 chimeric antigen receptor natural killer cell therapy (PersonGen Biomedicine) | Phase 2 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Leukemia; Lymphoma, T-Cell, Peripheral; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Prolymphocytic, T-Cell; Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Leukemia, Large Granular Lymphocytic | Details | |
CD7 targeted CAR-γδ T Cells (Persongen Bio) | Details | ||||
CD7-CAR-T cell therapy (PersonGen Biomedicine) | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd, The First Affiliated Hospital Of Zhengzhou University | Enteropathy-Associated T-Cell Lymphoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell | Details |
This web search service is supported by Google Inc.